Want to see NTLA full AI Analyst Report?
NTLA Stock Chart & Stats
$14.95
-$0.56(-4.53%)
At close: 4:00 PM EST
$14.95
-$0.56(-4.53%)
Day’s Range― - ―
52-Week Range$7.95 - $28.25
Previous CloseN/A
Volume723.92K
Average Volume (3M)6.92M
Market Cap
$2.41B
Enterprise Value$1.65B
Total Cash (Recent Filing)$375.99M
Total Debt (Recent Filing)$80.49M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Jul 30, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding139,722,270
10 Day Avg. Volume8,491,807
30 Day Avg. Volume6,918,805
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue24.99
Enterprise Value/Gross Profit-16.25
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
$21.06Price Target Upside40.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$59.03M
Bulls Say, Bears Say
Bulls Say
Clinical & Regulatory ProgressRobust Phase 3 data and a rolling BLA represent a structural inflection: a potential first-in-class, one-time CRISPR therapy could create a durable commercial franchise, validate the in vivo platform, and materially change long-term revenue and partnership dynamics if approved.
Strengthened Funding RunwayA sizable equity raise extending runway into 2028 materially reduces near-term financing pressure, allowing continued clinical development and commercial preparation for lead programs. This funding window improves execution optionality and supports durable program advancement.
Partnership/Collaboration ModelA partnership-driven revenue model provides non‑dilutive funding, shared R&D risk, and potential milestone/royalty income as programs progress. Strategic collaborations anchor technology adoption and offer durable funding and development support while the company scales commercialization capabilities.
Bears Say
High Cash Burn / Negative Cash FlowPersistent negative operating and free cash flow is a structural weakness: ongoing burn requires future financings or greater partner monetization, increasing execution risk and potential dilution. It constrains long-term investment choices and elevates dependency on capital markets or deals.
Large Ongoing Losses & Negative Gross ProfitDeep, persistent losses and a negative trailing gross profit imply the business is not yet generating scalable, margin-bearing revenue. This structural unprofitability undermines self-funding prospects and makes long-term viability contingent on successful product launches or continued external funding.
Equity Dilution & Eroding Capital BaseDeclining equity and recent share issuance to raise cash indicate shareholder dilution and erosion of the capital base. Repeated capital raises could persist until products generate revenue, reducing long-term per-share economics and increasing sensitivity to execution against clinical and regulatory milestones.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics Inc’s price range in the past 12 months?
Intellia Therapeutics Inc lowest stock price was $7.95 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics Inc’s market cap?
Intellia Therapeutics Inc’s market cap is $2.41B.
When is Intellia Therapeutics Inc’s upcoming earnings report date?
Intellia Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 27 days.
How were Intellia Therapeutics Inc’s earnings last quarter?
Intellia Therapeutics Inc released its earnings results on May 11, 2026. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.911 by $0.101.
Is Intellia Therapeutics Inc overvalued?
According to Wall Street analysts Intellia Therapeutics Inc’s price is currently Undervalued.
Does Intellia Therapeutics Inc pay dividends?
Intellia Therapeutics Inc does not currently pay dividends.
What is Intellia Therapeutics Inc’s EPS estimate?
Intellia Therapeutics Inc’s EPS estimate is -0.81.
How many shares outstanding does Intellia Therapeutics Inc have?
Intellia Therapeutics Inc has 139,722,270 shares outstanding.
What happened to Intellia Therapeutics Inc’s price movement after its last earnings report?
Intellia Therapeutics Inc reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.911. Following the earnings report the stock price went up 2.342%.
Which hedge fund is a major shareholder of Intellia Therapeutics Inc?
Currently, no hedge funds are holding shares in NTLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.06 (40.89% Upside)
$21.06 (40.89% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 49.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.49%
12-Months-Change
Fundamentals
Return on Equity
-57.27%
Trailing 12-Months
Asset Growth
-23.06%
Trailing 12-Months
Company Description
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of important clinical and commercial progress — most notably the completed Phase 3 enrollment and upcoming pivotal readout for lonvo-z, strong patient and physician interest, durable early efficacy signals, and improved near-term financial metrics — alongside meaningful risks: a still-pending FDA hold on the large cardiomyopathy ATTR program driven by serious liver enzyme events (including one patient death), material year-over-year cash depletion, and incomplete understanding of the safety signal’s mechanism and breadth. Management has secured a partial regulatory win (MAGNITUDE-2 hold lifted with specific mitigations) and emphasizes preparedness for a potential lonvo-z launch, but the unresolved MAGNITUDE hold and safety uncertainty inject non-trivial downside risk.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$21.06
▲(40.89% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―
Ownership Overview
1.57% Insiders
15.36% Mutual Funds
24.88% Other Institutional Investors
28.64% Public Companies and Individual Investors